– Patent on the composition for the prevention or treatment of cartilage damage, degenerative arthritis, etc.
– Already acquired similar patents in the US, Europe, China, Japan and Singapore

MEDIPOST announced on July 11 that it had obtained a Mexican patent on the composition for treating cartilage damage using stem cells.

This patent is entitled, “TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and the applications thereof.”

This patent is a composition patent for the prevention or treatment of cartilage damage, cartilage degeneration, cartilage defects and degenerative arthritis, and the composition includes cells expressing the TSP-2.

MEDIPOST has now acquired division patents in Mexico after 2016, and has acquired patents on the methods for screening cells with superior cartilage differentiation and secreted proteins related to the cartilage damage treatment.

MEDIPOST has already acquired similar patents in Korea, United States, Europe, China, Japan, and Singapore, and has been applying them to “CARTISTEM^®”, which is produced in Korea.

Meanwhile, CARTISTEM^®, is a form of treatment for knee cartilage defects in patients with osteoarthritis due to degenerative or repetitive trauma and it was approved as the world’s first allogeneic cord blood-derived stem cell therapy in 2012.